ArticleMolecular biology reports2026
Role of epigallocatechin gallate on aluminum exposure-induced bone damage via NLRP3 inflammasome signaling pathway.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAluminum (Al) residue in the ecosystem has been increasing significantly, making Al exposure inevitable. Al has been shown to inhibit bone formation and cause osteoporosis. Epigallocatechin gallate (EGCG), which is one of the primary polyphenols found in green tea, has shown positive impacts on bone health; however, its possible therapeutic role in preventing Al-induced bone damage remains insufficiently explored. The study aimed to examine the effect of EGCG on Al-induced bone damage possibly through modulation of the NLRP3 inflammasome pathway.
methodsRats were exposed to AlCl₃ to induce bone damage and treated with different doses of EGCG. Bone and serum mineral levels were determined using biochemical analyses. Relative mRNA expression levels of NLRP3, caspase-1, IL-1β, OPN, and OCN in bone tissue were evaluated by RT-PCR analysis and bone IL-1β levels were determined by ELISA.
resultsAlCl
conclusionsThese findings suggest that Al-induced bone damage may be associated with activation of the NLRP3 inflammasome pathway and that EGCG may exert protective effects, through modulation of this pathway. Thus, it was concluded that EGCG may be a promising protective agent for preventing Al-induced bone damage and may serve as a potential preventive agent for the treatment of bone diseases.
Indexed as
Identifiers
42384287What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.